

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



金威医疗集团有限公司

Good Fellow Healthcare Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

SUPPLEMENTAL ANNOUNCEMENT

INSIDE INFORMATION BUSINESS UPDATE

This announcement is made by Good Fellow Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10(2) of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 13 December 2024 (the “**Announcement**”) in relation to, among others, the business update of Beijing Huicheng. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those set out in the Announcement.

The Board wishes to provide further information to the shareholders (the “**Shareholders**”) and potential investors of the Company in relation to the reasons leading to the temporary suspension (the “**Temporary Suspension**”) of the operations of Beijing Huicheng, and the Group’s plan and expected timetable to resume the operations of Beijing Huicheng.

As disclosed in the Announcement, following the resumption of operation of Beijing Huicheng in or around April 2024, the recovery of its business had not been satisfactory. In the circumstances, the Board proposed to relocate Beijing Huicheng and upgrade it to a Grade II general hospital (the “**Proposed Upgrade and Relocation**”) with a view to improve the Group’s financial performance and enhance return to the Shareholders.

In or around November 2024, the management of Beijing Huicheng made a written request to the Health Commission in respect of the Proposed Upgrade and Relocation, and applied for the postponement of the annual inspection as additional time is required to identify suitable sites for the proposed relocation. The Health Commission has granted an approval in principle, but required Beijing Huicheng to suspend its operations and identify the new site (the “**New Site**”) prior to December 2025. As such, the Board has resolved to apply for the Temporary Suspension.

It is expected that the New Site will remain in the Dongcheng District of Beijing, with an increased gross site area which would entitle Beijing Huicheng to admit more patients. Nevertheless, if other suitable sites are available, the Board will not rule out the possibility to relocate Beijing Huicheng to districts outside the Dongcheng District of Beijing. After completion of the Proposed Upgrade and Relocation, Beijing Huicheng shall provide comprehensive general hospital services, covering, among others, general medical consultations, prescription of medications and complex surgical operations.

Set out below is the detailed plan and timetable of the Group for the resumption of operations of Beijing Huicheng:

Expected Date	Event(s)
on or before 31 May 2025	The management of Beijing Huicheng to (i) conduct market research to understand the actual demand for medical services, and devise its business strategy; (ii) identify suitable sites for resumption of operation of Beijing Huicheng based on, among other criteria, accessibility, surrounding facilities and site area; (iii) sign a letter of intent with the relevant lessor in relation to the leasing of the New Site; and (iv) prepare the relevant documents and materials in relation to the resumption of operation of Beijing Huicheng, including not but not limited to the application for the establishment of medical institution, feasibility study report, site selection report and floor plan of the New Site (collectively, the “ Resumption Materials ”).

Expected Date	Event(s)
on or before 31 July 2025	The management of Beijing Huicheng to (i) submit to the Health Commission the Resumption Materials and if requested, provide any supplemental documents and/or materials; and (ii) subject to the approval of the Health Commission, sign the formal lease agreement with the relevant lessor in relation to the leasing of the New Site, and proceed with all necessary registration procedures.
on or before 1 August 2025	Commencement of the renovation of the new hospital in compliance with the specifications of a Grade II general hospital. Medical equipment will be procured by way of tender in accordance with the established procurement procedures and policy of the Group.
on or before 15 October 2025	Completion of the renovation of the new hospital. Supplier to deliver and install the relevant medical equipment and information technology technician to construct the information system for the new hospital, including but not limited to hospital information system (HIS) and electronic medical record system (EMR).
on or before 31 October 2025	The management of Beijing Huicheng to (i) recruit experienced and qualified medical practitioners and healthcare-related staff; (ii) provide induction training to the new employees, and based on their specialties and positions, offer professional skills training, such as clinical skills training, nursing skill training, and surgical operation training; and (iii) arrange for simulation of operation to familiarise the employees with the workflow and operations of the new hospital.
on or before 15 November 2025	Completion of all necessary registration procedures. The management of Beijing Huicheng to (i) seek the Health Commission's approval in relation to the re-issue of the Medical Institution Practising Certificate; and (ii) conduct comprehensive pre-opening inspections, including but not limited to the operation of the medical equipment, sufficiency of medical staff and medical hygiene, ensuring that the services to be provided by Beijing Huicheng conforms to the standard of a Grade II general hospital in the PRC.
on or before 1 December 2025	Re-issue of the Medical Institution Practising Certificate and resumption of operations of Beijing Huicheng.

The working capital required for the operation of the general hospital business of the Group will be supported by shareholder's loan and internal resources of the Group. Should suitable opportunities arise, the Company may also consider conducting equity and/or debt fundraising exercise to expand its general hospital business and support future development of the Group.

The Company will keep the Shareholders and potential investors of the Company informed of any material developments in connection with the above by way of further announcement(s) as and when appropriate and in accordance with the requirements of the GEM Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Good Fellow Healthcare Holdings Limited
Ng Chi Lung
Chairman and Executive Director

Hong Kong, 10 February 2025

As at the date of this announcement, the Board comprises Mr. Ng Chi Lung and Mr. Wu Qiyou as executive Directors; and Ms. Wong Ka Wai, Jeanne, Mr. Lau Tak Kei Arthur and Mr. Lin Yaomin as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the website of the Stock Exchange at www.hkexnews.hk on the "Latest Listed Company Information" page of the website of the Stock Exchange for at least seven days from the date of its publication and on the website of the Company at www.gf-healthcare.com.